Pivotal Study of Boston’s SYNERGY™ Coronary Stent System Completes Enrollment

Boston Scientific Corporation has completed enrollment in the EVOLVE II randomized, controlled clinical trial of its SYNERGY™Stent System. The safety and efficacy study will support U.S. FDA and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.

Boston Scientific Concludes Enrollment In Randomized, Multicenter, Pivotal Study Of SYNERGY™ Coronary Stent System (via PR Newswire)

NATICK, Mass., Sept. 12, 2013 /PRNewswire/ — In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™Stent System, Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the EVOLVE II randomized…

published: September 16, 2013 in: Boston Scientific, Cardio, Clinical Studies/Trials

Most read

Latest

^